Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN 5% vs AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Amino acids provide substrates for protein synthesis and metabolic processes; dextrose supplies glucose for energy; electrolytes maintain fluid and electrolyte balance.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
Intravenous infusion: 500 mL/day initially, titrate to provide 1.5-2 g/kg/day of amino acids and 25-50 g/kg/day of dextrose; monitor electrolytes.
None Documented
None Documented
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Amino acids: 0.5-2 hours (rapid clearance); dextrose: ~1-2 hours (insulin-dependent). Clinical context: Continuous IV infusion maintains steady state.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Renal (amino acids: ~80% reabsorbed, excess excreted unchanged; dextrose: primarily metabolized, small fraction excreted renally <5%; electrolytes: renal excretion proportional to intake and plasma levels).
Category C
Category C
Amino Acid Solution
Amino Acid Solution